Natco Pharma Reports Q1 FY26 Earnings, Cites Revlimid Pressure and Strategic Investments
The announcement includes the company's Q1 financial results, updates on a significant strategic acquisition (Adcock Ingram), the outlook for a major revenue-contributing drug (Revlimid), progress on key pipeline products (Semaglutide, Pomalidomide), and future investment plans (R&D, authorized capital increase). These elements provide crucial insights into the company's current performance and future strategic direction, making the announcement highly impactful for investors.
The Q1 FY26 financial results show a slight dip in revenue and net profit primarily due to pricing pressure on Revlimid and increased R&D expenses. However, the company is undertaking significant strategic initiatives like the Adcock Ingram acquisition for diversification, investing in high-value R&D projects, and progressing on key product launches (Semaglutide, Pomalidomide), which are expected to yield future benefits. The current quarter's performance is mixed, but the long-term outlook appears positive due to these strategic moves.
* Natco Pharma Limited reported consolidated total revenue of INR1,390.6 crores for the quarter ended June 30, 2025, compared to INR1,410.7 crores in the same period last year. * EBITDA for the quarter stood at INR632.7 crores with margins at 45.5%. Net profit on a consolidated basis was INR480.3 crores. * The company declared an interim dividend of INR2 per equity share during the quarter. * Performance was impacted by pricing pressure in the U.S. product portfolio, primarily from Revlimid, which is expected to see further decline post-September quarter FY26. * Increased R&D expenses on high-value projects, particularly cancer products requiring clinical trials and peptides/oligopeptides, also contributed to higher other expenses. These major R&D expenditures are concentrated in Q1 and Q2 FY26 and are expected to decline from the December quarter. * Segment-wise, API business clocked INR52.6 crores, domestic formulation INR107 crores, and formulation exports (including profit share and subsidiaries) INR1,126.5 crores. Crop Health Sciences contributed INR34.7 crores, nearing breakeven with a loss of INR3.2 crores this quarter, supported by new product launches like GLANZ. * The acquisition of a 35.75% stake in South African company Adcock Ingram, a ₹2,000 crores investment, is expected to complete in the next 2-3 months, subject to regulatory clearances. This strategic move aims to diversify earnings and strengthen the company's base business, with Adcock potentially contributing 15-25% of NATCO's PAT by FY27 (excluding Revlimid). * The company is seeking an increase in authorized capital as an enabling resolution for potential future large transactions to strengthen its base business. * Regarding manufacturing facilities, the Mekaguda API facility received EIR clearance. For the Kothur facility, responses to multiple observations from an FDA inspection in July have been submitted, and the company is cautiously optimistic for a positive resolution within 90 days. * In its pipeline, the Semaglutide launch in India is on track for market formation next year (FY27), with Phase I dosing complete and readout expected by November/December. Pomalidomide in the U.S. has full approval with a settlement, but the launch date is confidential. * Investments in new chemical entities (NCE) and Cell & Gene therapies include Eyestem (dry age-related macular degeneration) and eGenesis (genetically modified pig transplants), with eGenesis showing promising data. * Management did not provide specific FY27 guidance due to various "moving parts" in the business.
What to do with a filing like this
Natco Pharma Limited filed this with the NSE as a statutory disclosure, categorised under results. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Natco Pharma Limited. Read the original for the full detail.